Viewing nowCombinationVivas Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dae Hwa Pharmaceutical Co., Ltd.

MFDS item code 201500471 · Approved 2015.01.29 · Insurance code 645604520
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension who have difficulty achieving blood pressure control with monotherapy using either amlodipine or olmesartan medoxomil.
Administer 1 tablet of this drug once daily with water, without regard to meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this drug must not be administered under Precautions for Use.) ∘Older adults: Generally, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.
The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with hypersensitivity to the active ingredient or similar components, pregnant or nursing women, those with severe liver dysfunction, aortic stenosis, biliary obstruction, renal dialysis patients, patients in shock, or certain diabetic patients. In patients with low fluid or sodium levels, hypotension may occur, so careful monitoring of their condition should be conducted during initial administration. Patients with aortic stenosis should be particularly cautious due to potential rapid decreases in blood pressure from vasodilation. This medication may affect the condition in patients with heart disease or heart failure, so it should be used with caution. In patients with impaired kidney function, it can worsen kidney function, so it should be administered cautiously. Patients with decreased liver function may also be affected in drug metabolism, so caution is necessary. Side effects such as dizziness, headaches, hypotension, cough, dyspepsia, rash, edema, and others may occur during treatment. Especially, since potassium levels in the blood may increase, regular blood tests may be necessary. Care should be taken to avoid drug interactions, and co-administration with grapefruit juice should be avoided as it can enhance the blood pressure-lowering effect. This medication should not be used during pregnancy, and if planning for pregnancy, it is recommended to switch to other safe antihypertensive agents. Nursing women should discontinue breastfeeding or the use of this medication as it may be transmitted through breast milk and could cause side effects in infants. Safety and efficacy in pediatric patients under 18 years of age have not been established, so it is not recommended for them. In elderly patients, drug metabolism and excretion may slow down, so it's important to start with a low dose and adjust it carefully. In cases of overdose, severe hypotension and vasodilation may occur, requiring immediate medical attention for appropriate treatment. Store this medication out of reach of children and protect it from moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve the efficacy and safety of the medication for as long as possible.
Pale yellow round film-coated tablet
28 tablets/box [14 tablets/blister x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dae Hwa Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.